Alloy Therapeutics has raised $165M across 1 funding round, plus 3 undated rounds. The latest round valued Alloy Therapeutics at $1B post-money.
Alloy Therapeutics counts 8VC among its investors, which lists the company in its life-sciences portfolio alongside other biotechnology ventures.
1 funding round, the latest highlighted.
Alloy Therapeutics was founded in 2011, United States.
No date is disclosed for this round.
8VC, JIC Venture Growth Investments, Echo Capital, Mubadala Capital, Presight Capital, Thiel Capital, Founders Fund, Alexandria Venture Investments, Gaingels, Ulysses Diversified Holdings. $40M raised.
No filing has been made.
1 dated round, newest first.
8VCLEADMMubadala CapitalLEADFFelicisLEADPPeter ThielLEADJJIC Venture Growth InvestmentsEEcho CapitalPPresight CapitalTThiel Capital
Founders FundAAlexandria Venture InvestmentsThe routes section explains what is realistically available for a company at this stage.
No. Alloy Therapeutics is a private company; its shares do not trade on a public exchange.
The last valuation is $1B.
Lead investors for each round are in the funding timeline.
The closest biotech peers are on the competitors page.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
